Viewing data from:

CHOLESTYRAMINE

ANDA

CHOLESTYRAMINE | A074347 | TEVA PHARMACEUTICALS USA INC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Cholestyramine (2023)

Total Spending

$47.7M

Total Claims

471,412

Beneficiaries

186,287

Avg Cost/Unit

$1.17

Spending Trend

$52.6M(2019)→$53.9M(2020)→$53.4M(2021)→$52.4M(2022)→$47.7M(2023)

YoY Change:-9.7%

5yr CAGR:-4.2%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs2 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

PUROLITE LLCCHOLESTYRAMINE RESIN USP

DMF 73241988

ION EXCHANGE INDIA LTDCHOLESTYRAMINE RESIN USP (INDION 454)

DMF 231712009

PHAEX POLYMERS PRIVATE LTDCHOLESTYRAMINE RESIN USP AS IN

DMF 276072013

DOW CHEMICAL COInactiveCHOLESTYRAMINE USP

DMF 57591985

ROHM AND HAAS COInactiveCHOLESTYRAMINE RESIN, USP-AMBERLITE IRP-276

DMF 65061986

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
May 28, 1998	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 4GM RESIN/PACKET

0 patents0 exclusivities▴

POWDER;ORAL | Approved: May 28, 1998

No patent or exclusivity listings for this strength.

#002 — EQ 4GM RESIN/SCOOPFUL

0 patents0 exclusivities▾

POWDER;ORAL | Approved: May 28, 1998